Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Zanubrutinib for Maintenance Therapy in Patients With Mantle Cell Lymphoma Who Have Remission After First-line Immunochemotherapy- a Multicenter, Prospective, Phase II Study

NCT06341556 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06341556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06341556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Zanubrutinib for Maintenance Therapy in Patients With Mantle Cell Lymphoma Who Have Remission After First-line Immunochemotherapy- a Multicenter, Prospective, Phase II Study
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
May 24, 2024
Completion date
June 30, 2028
Enrollment
52 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

maintenance therapy, mantle cell lymphoma